#Australia #Melbourne #ALS #Neurizon #NUZ-001

Neurizon Completes Enrolment for HEALEY ALS Trial

On July 16, 2026, Neurizon Therapeutics Limited announced a significant milestone in its journey towards combating amyotrophic lateral sclerosis (ALS). The company successfully completed the enrolment phase for Regimen I of the HEALEY ALS Platform Trial, achieving this remarkable feat in under five months since the first dosing of participants.

Record-Breaking Enrolment Speed

A total of 250 participants were enrolled, marking this as the fastest activation and enrolment in the trial's history. This rapid pace not only reflects the enthusiasm of patients willing to participate but also illustrates the robust recruitment strategies applied throughout the HEALEY ALS Platform Trial network. The swift completion comes on the heels of a decision to expand the sample size from an initial goal of 160 participants to accommodate the rising interest and continuous recruitment momentum.

Neurizon plans to present topline efficacy and safety results for its investigational therapy, NUZ-001, in late Q2 2027—an earlier timeline than originally projected. The anticipated results represent a critical inflection point not only for Neurizon but also for the entire ALS community, striving for effective treatment options.

Commitment to Advance Clinical Research

The successful enrolment in this trial is due in part to the collaboration between Neurizon and key stakeholders in the medical field, including the Sean M. Healey AMG Center for ALS at Mass General Brigham. Dr. Merit Cudkowicz, Executive Director of the neuroscience institute, noted the importance of rapid and efficient trials. The new methodologies adopted in this innovative study facilitate quick participant onboarding and high-quality evaluations, all aimed at ensuring that new treatments reach patients promptly.

The trial methodology reflects a commitment to understanding and overcoming the challenges associated with ALS. Participants are now set to embark on a robust protocol, which involves a 36-week randomized treatment period followed by an additional 36-week Active Treatment Extension.

Acknowledgment of Participants

Neurizon has pointedly expressed gratitude towards those living with ALS who have enrolled in this research trial. Their courage in contributing to science—despite the personal trials associated with the disease—forms the backbone of medical advancements in ALS therapies. The involvement of their families underscores the community's collective fight against ALS, making every participant's decision to join the study invaluable.

Operational Focus Ahead

As the team gears up for the next phases of the trial, operational discipline remains a top priority. Interim Executive Chairman of Neurizon, Mr. Sergio Duchini, has affirmed that the company is committed to maintaining the high operational standards that have characterized the trial thus far. He emphasizes the essential role of speed and efficiency in bringing forth new treatment solutions for ALS patients.

With the enrolment now complete, Neurizon stands at the ready to continue its pioneering work, looking forward to the upcoming results that could provide hope for countless patients affected by ALS. The anticipated topline readout in late Q2 2027 is viewed not just as a culmination of clinical research effort, but as a beacon of hope for those battling this challenging disease. Neurizon Therapeutics continues to lead the charge in striving for advancements that promise to improve the quality of life for ALS patients around the world.

Conclusion

As the HEALEY ALS Platform Trial progresses, the robust data collected through this initiative will be instrumental in guiding future ALS therapies. Neurizon’s proactive approach and unwavering commitment to improving the lives of those affected by neurodegenerative diseases will undoubtedly set the stage for significant breakthroughs in treatments and patient care.

For additional information on Neurizon’s initiatives or to stay updated on their progress, please visit their Investor Hub.